Valuation: Monopar Therapeutics Inc.

Market Cap 782M 675M 633M 577M 1.08B 74.76B 1.1B 7.42B 2.91B 37.45B 2.94B 2.87B 125B P/E 2026 *
-46.7x
P/E 2027 * -46.5x
Enterprise Value 663M 572M 537M 489M 920M 63.41B 933M 6.3B 2.47B 31.77B 2.49B 2.44B 106B EV / Sales 2026 *
-
EV / Sales 2027 * 22.6x
Free-Float
76.63%
Yield 2026 *
-
Yield 2027 * -
1 day-0.81%
1 week+1.00%
Current month+6.69%
1 month+9.16%
3 months+105.51%
6 months+108.36%
Current year+77.03%
1 week 107.78
Extreme 107.78
118.2
1 month 101
Extreme 101
124.82
Current year 50.07
Extreme 50.07
124.82
1 year 29.18
Extreme 29.18
124.82
3 years 1.37
Extreme 1.3695
124.82
5 years 1.37
Extreme 1.3695
124.82
10 years 1.37
Extreme 1.3695
240
Manager TitleAgeSince
Chief Executive Officer 42 30/11/2014
Director of Finance/CFO 54 02/03/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 42 30/11/2014
Chairman 73 30/11/2014
Director/Board Member 84 31/03/2017
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Fiscal year

Chief Financial Officer

2,963 0.0442%
30/06/26 Fiscal year

Chief Operating Officer

12,817 0.1913%
30/06/26 Fiscal year

Founder

29,830 0.4453%
Change 5-day change 1-year change 3-year change Capi.($)
-0.81%+1.00%+237.42%+3,471.21% 782M
-0.11%-1.67%+1.80%+19.90% 48.84B
+0.39%+3.48%+483.55%+618.11% 45.44B
+1.66%+2.27%+15.06%+90.32% 41.22B
+0.82%-0.40%+26.14%+13.50% 39.71B
-2.74%-2.74%+17.30%+56.10% 32.6B
+1.06%-1.53% - - 16.25B
-0.62%-1.95%+28.25%+137.78% 16.67B
-0.49%-0.34%+3.45%+29.14% 14.08B
-1.00%+0.53%+80.59%+42.53% 13.68B
Average -0.18%-0.69%+99.28%+497.62% 26.93B
Weighted average by Cap. +0.05%-0.84%+103.12%+162.63%

Financials

2026 *2027 *
Net sales - 28.26M 24.4M 22.89M 20.85M 39.2M 2.7B 39.74M 268M 105M 1.35B 106M 104M 4.5B
Net income -21.46M -18.53M -17.38M -15.83M -29.77M -2.05B -30.18M -204M -79.86M -1.03B -80.58M -78.84M -3.42B -26.62M -22.98M -21.56M -19.63M -36.92M -2.54B -37.43M -253M -99.03M -1.27B -99.93M -97.77M -4.24B
Net Debt -119M -103M -96.18M -87.61M -165M -11.35B -167M -1.13B -442M -5.69B -446M -436M -18.92B -145M -125M -117M -107M -201M -13.82B -203M -1.37B -538M -6.92B -543M -531M -23.04B
Logo Monopar Therapeutics Inc.
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Employees
-
Date Price Change Volume
18/08/26 US$115.90 -0.51% 61,826
17/08/26 US$116.49 +3.05% 171,114
14/08/26 US$113.04 +2.38% 165,721
13/08/26 US$110.41 -3.91% 162,521
12/08/26 US$114.90 +0.38% 354,197
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
116.49USD
Average target price
126.31USD
Spread / Average Target
+8.43%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MNPR Stock